P/E ratio for Sangamo Therapeutics (SGMO)

P/E ratio history for Sangamo Therapeutics from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Gilead Sciences GILD	18.5	-1,905.59%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	> 1000	-432,004.80%	🇺🇸 USA
Amgen AMGN	24.4	-2,484.33%	🇺🇸 USA
Biogen BIIB	15.8	-1,648.96%	🇺🇸 USA
Dow DOW	-14.8	1,346.75%	🇺🇸 USA
Johnson & Johnson JNJ	20.3	-2,081.70%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	19.6	-2,016.37%	🇺🇸 USA
Merck MRK	13.2	-1,391.47%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.